Noticias - Desert King

Adeagbo, B.A., et al. Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuberculosis Vaccine Formulation (ID93 + GLA-LSQ).

Adeagbo, B.A., et al. Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuber...

Madden, P.J., et al. Diverse priming outcomes under conditions of very rare precursor B cells.

Madden, P.J., et al. Diverse priming outcomes under conditions of very rare precursor B cells. Immunity, 2025 Apr 8, 58(4):997-1014.e11. PMID: 40168992 The paper investig...

Song, Y., et al. 50-Fold Adjuvant and 20-Fold Antigen Vaccine Dose Sparing from Nanoliposome Display of a Stabilized Malarial Protein Antigen.

Song, Y., et al. 50-Fold Adjuvant and 20-Fold Antigen Vaccine Dose Sparing from Nanoliposome Display of a Stabilized Malarial Protein Antigen. CS Nano, 2025 Mar 18, 19(1...

Pal, P.B. and Lyer, S.S. Transient pain and long-term gain: adjuvant dose directs immune memory.

Pal, P.B. and Lyer, S.S. Transient pain and long-term gain: adjuvant dose directs immune memory. J Clin Invest, 2025 Apr 15, 135(8):e190524. PMID: 40231461 The paper disc...

Ramezani-Rad, P., et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.

Ramezani-Rad, P., et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates. J Clin Invest, 2025 M...

Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.

Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 ...

Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.

Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over...

Ye, L., et al. Effects of immune response on different nano-adjuvants combined with H11 antigen of Haemonchus contortus.

The study indicates that nano-adjuvants offer a promising alternative to traditional adjuvants for inducing robust and lasting immune responses